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OBJECTIVE—We examined the association between retinol-binding protein 4 (RBP4), a
novel adipokine, and prediabetes (isolated impaired fasting glucose [i-IFG], isolated impaired
glucose tolerance [i-IGT], and combined IFG and IGT) in men and women aged 32–81 years.
RESEARCH DESIGN AND METHODS—The analysis was based on 2,614 participants
without previously diagnosed diabetes and those with newly diagnosed diabetes of the Co-
operative Health Research in the Region of Augsburg (KORA) F4 Study, conducted from 2006
to 2008 in southern Germany. Plasma RBP4 was analyzed by immunonephelometry.
RESULTS—In logistic regression analysis, RBP4 levels in the fourth quartile versus the ﬁrst
quartile were signiﬁcantly associated with prediabetes (i-IGT, i-IFG, and IFG/IGT; reference
normal glucose tolerance) independent of known metabolic risk factors and lifestyle variables
(odds ratio 1.63 [95% CI 1.17–2.27] after multivariable adjustment). Stratiﬁcation by sex
showed generally similar results.
CONCLUSIONS—RBP4 levels were associated with prediabetes in individuals from the
general population. Prospective studies investigating the impact of RBP4 on the development
of glucose intolerance are needed.
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R
etinol-binding protein 4 (RBP4),
the speciﬁc transport protein for
retinol (vitamin A) in the blood (1),
is a novel adipokine that is secreted from
adipocytes and hepatocytes. Although
studies in mice have suggested that ele-
vated RBP4 levels may play a causal role
in the development of insulin resistance
and type 2 diabetes, previous studies in
humans on this issue are controversial
(2–5). Most studies investigating this
association so far were based on very
small sample sizes (2,6) and on groups
at high risk of insulin resistance and fu-
turedevelopmentoftype2diabetes(7,8).
To date, no population-based data are
available to determine whether RBP4 in-
ﬂuencestheriskforprediabetes.Therefore,
the current study set out to investigate the
possible association between RBP4 levels
and prediabetic groups (isolated impaired
fasting glucose [i-IFG], isolated impaired
glucose tolerance [i-IGT], and combined
IFG and IGT) in a population of men and
women aged 32–81 years in southern
Germany.
RESEARCH DESIGN AND
METHODS—Data are based on the
Cooperative Health Research in the Re-
gion of Augsburg (KORA) F4 Study
(2006–2008), a follow-up of the KORA
S4 study, a population-based health sur-
vey conducted between 1999 and 2001.
Altogether, 3,080 subjects participated in
theKORAF4study(responserate79.6%)
(9). The current study was restricted to
2,614 subjects without previously diag-
nosed diabetes (n = 235) and those with
newly diagnosed diabetes (n =1 0 8 )o r
missing values on any of the analytical
variables (n = 123). The investigations
were carried out in accordance with the
Declaration of Helsinki and included
written informed consent from all par-
ticipants. All study methods were
approved by the ethics committee of
the Bavarian Chamber of Physicians
(Munich, Germany).
After an overnight fast of at least
10 h, all nondiabetic participants under-
went a standard 75-g oral glucose toler-
ance test (10). Newly diagnosed diabetes,
i-IGT, i-IFG, and normal glucose toler-
ance (NGT) were deﬁned according to
the 1999 World Health Organization di-
agnosticcriteria(9).Informationonsocio-
demographic variables, lifestyle, and risk
factors was gathered during a standard-
ized interview. All participants underwent
an extensive standardized medical exami-
nation, as described in more detail else-
where (11).
Clinical chemical measurements
A fasting venous blood sample was ob-
tained from all study participants while
sitting. Blood glucose; HbA1c; triglycer-
ides; and total, LDL, and HDL cholesterol
were determined, as described elsewhere
(9). Plasma concentrations of RBP4 were
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280°C) by immunonephelometry using
a BN II analyzer. The interassay coefﬁ-
cient of variation was ,10%.
Statistical analyses
The study population was stratiﬁed into
quartiles of RBP4 concentrations with use
ofcutpointsof0.039,0.045,and0.052g/L
for men and 0.033, 0.038, and 0.045 g/L
for women (25th, 50th, and 75th percen-
tiles, respectively). In logistic regression
analysis, the association between RBP4
and prediabetic groups (i-IFG, i-IGT, and
IFG/IGT; reference group NGT) as the
outcome was investigated. Odds ratios
and 95% CIs were computed for the
second, third, and fourth quartiles com-
paredwiththelowestquartileindifferent
stepwise regression models. A P value of
,0.05wasconsideredstatisticallysignif-
icant. All analyses were performed using
SAS software, version 9.1 (SAS Institute,
Cary, NC).
RESULTS—There were 2,122 partic-
ipants in the study with NGT, 110 with
i-IFG, 313 with i-IGT, and 69 with com-
bined IFG/IGT. Higher RBP4 levels were
associated with a higher prevalence of
impaired glucose regulation, as well as
agreaterfrequencyofobesity,hyperten-
sion, and higher alcohol consumption.
Furthermore, higher RBP4 levels were as-
sociated with a more advanced age and
higher BMI, waist circumference, total
cholesterol, LDL cholesterol, triglyceride,
fasting glucose, 2-h glucose, and HbA1c
values.
In the total sample, odds ratios in-
creased with increasing RBP4 concentra-
tions, but only RBP4 levels in the fourth
quartilewere signiﬁcantly associated with
prediabetes independent of age, sex,
actual hypertension, regular smoking,
alcohol intake, physical activity, and ed-
ucation (model 3: odds ratio 1.77 [95%
CI 1.30–2.41]). Additional adjustment
for BMI, HbA1c, and total cholesterol val-
ues (model 5) attenuated the association,
but it remained statistically signiﬁcant;
comparing the highest versus the lowest
quartile of RBP4, the odds ratio for im-
paired glucose regulation was 1.63 (95%
CI 1.17–2.27) (Table 1). Stratiﬁcation by
sex showed generally similar results,
with a somewhat stronger association in
womenthaninmen(Table1).Therewere
no signiﬁcant interactions between RBP4
and sex.
When RBP4 was included as a con-
tinuous variable in the models, it also was
signiﬁcantly associated with prediabetes
after multivariable adjustment (model 5:
odds ratio per SD change 1.20 [95% CI
1.08–1.34]; data not shown).
CONCLUSIONS—In the current
study, RBP4 levels were positively associ-
ated with metabolic risk factors, such as
BMI,waistcircumference,actualhyperten-
sion, and lipid parameters. Furthermore, a
signiﬁcant relationship between plasma
concentrations of RBP4 and prediabetes
was seen. These associations were inde-
pendent of known metabolic risk factors
and lifestyle variables.
To date, studies on the association
between RBP4 and glucose metabolism
based on men and women from the
general population are scarce. In a recent
cross-sectional study conducted in Chi-
nese adults aged $40 years, it was found
that increased RBP4 levels increased the
risk for hyperglycemia, including im-
paired glucose regulation and newly di-
agnosed type 2 diabetes, even after
adjustment for a number of confounders
(12). An additional previous study (6)
b a s e do nav e r ys m a l ls a m p l eo f1 5 4
Table 1—Association between RBP4 levels and prediabetes (i-IFG, i-IGT, and combined IFG and IGT)
RBP4
P for trend Quartile 1 Quartile 2 Quartile 3 Quartile 4
Total sample (n =2 , 6 1 4 )
n 610 609 719 676
Model 1* 1.0 1.07 (0.78–1.46) 1.33 (0.99–1.78) 2.06 (1.55–2.73) ,0.01
Model 2† 1.0 1.09 (0.78–1.52) 1.24 (0.91–1.69) 1.84 (1.36–2.48) ,0.01
Model 3‡ 1.0 1.12 (0.80–1.57) 1.21 (0.88–1.66) 1.77 (1.30–2.41) ,0.01
Model 4§ 1.0 1.14 (0.81–1.61) 1.16 (0.84–1.60) 1.72 (1.25–2.36) ,0.01
Model 5|| 1.0 1.07 (0.75–1.52) 1.05 (0.75–1.47) 1.63 (1.17–2.27) ,0.01
Men (n = 1,228)
n 272 304 330 322
Model 1* 1.0 1.07 (0.70–1.61) 0.98 (0.65–1.48) 1.66 (1.12–2.45) 0.01
Model 2† 1.0 1.30 (0.84–2.02) 1.17 (0.76–1.81) 1.82 (1.21–2.76) ,0.01
Model 3‡ 1.0 1.33 (0.85–2.09) 1.05 (0.67–1.65) 1.69 (1.10–2.61) 0.04
Model 4§ 1.0 1.37 (0.86–2.18) 1.10 (0.69–1.76) 1.70 (1.09–2.66) 0.05
Model 5|| 1.0 1.36 (0.84–2.19) 1.00 (0.62–1.62) 1.58 (1.00–2.51) 0.13
Women (n = 1,386)
n 338 305 389 354
Model 1* 1.0 0.99 (0.61–1.62) 1.79 (1.17–2.74) 2.57 (1.70–3.90) ,0.01
Model 2† 1.0 0.84 (0.50–1.41) 1.25 (0.80–1.96) 1.80 (1.16–2.80) ,0.01
Model 3‡ 1.0 0.88 (0.53–1.48) 1.30 (0.83–2.04) 1.81 (1.16–2.84) ,0.01
Model 4§ 1.0 0.90 (0.53–1.53) 1.19 (0.75–1.88) 1.77 (1.12–2.80) ,0.01
Model 5|| 1.0 0.78 (0.45–1.35) 1.08 (0.67–1.74) 1.71 (1.06–2.77) ,0.01
Reference group:NGT.KORA F4participantswere aged 32–81years.*Crudemodel.†Adjustedfor age andsex(onlytotalsample). ‡Adjustedfor age,sex(onlytotal
sample), education, actual hypertension, regular smoking, physical activity, and alcohol intake. §Adjusted for age, sex (only total sample), education, actual hyper-
tension, regular smoking, physical activity, alcohol intake, and BMI. ||Adjusted for age, sex (only total sample), education, actual hypertension, regular smoking,
physical activity, alcohol intake, BMI, total cholesterol, and HbA1c.
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Meisinger and Associatesparticipants also reported that plasma
RBP4 levels were elevated in subjects
with IGT or type 2 diabetes and that
RBP4 was related to various clinical pa-
rameters known to be associated with in-
sulin resistance. Another small study (13)
conducted in Mexican Americans demon-
strated that plasma RBP4 levels are ele-
vated in subjects with type 2 diabetes
and correlate with measures of glycemia
but do not correlate with insulin sensi-
tivity.
The cross-sectional design of the
study represents a limitation, implicating
thatcause-and-effectrelationshipscannot
be discerned. Furthermore, we cannot
exclude that unknown risk factors may
have biased or confounded the present
analysis. Finally, the current study may
have low power to detect a signiﬁcant
association between the second and third
quartiles and prediabetes.
In conclusion, plasma concentrations
of RBP4 were independently associated
with prediabetes in individuals from the
general population. Additional studies, in
particular prospective studies, are needed
to investigate the contribution of RBP4 to
the pathogenesis of impaired glucose
regulation.
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